Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N,N-dimethyltryptamine nicotinate
- Development stage
- Unknown
- Lead developer
- Algernon NeuroScience
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous (investigational)
01
Overview
N,N-dimethyltryptamine nicotinate is a novel salt form of the psychedelic compound N,N-dimethyltryptamine (DMT), in which DMT is paired with the counterion nicotinate (derived from niacin/vitamin B3). This salt form was developed to potentially improve physicochemical properties such as stability, efficacy, and safety compared to other DMT salts. DMT itself is a potent serotonergic hallucinogen that acts primarily as an agonist at serotonin 5-HT2A receptors and also interacts with sigma-1 receptors. The addition of the bioactive counterion, nicotinate, may provide additional neuronal activity or neuroprotective effects independent of DMT. This combination is being investigated for its potential use in treating acute ischemic stroke and possibly other neurological conditions[7][9].
- Other names
- DMT nicotinatedimethyltryptamine nicotinate
02
Targets
HTR2A (Serotonin receptor 5-HT2A)SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on N,N-dimethyltryptamine nicotinate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on N,N-dimethyltryptamine nicotinate.